<html>
        <head>
            <link rel="stylesheet" type="text/css" href="layout.css" />
        </head>
        <style> 
            .right { 
                margin-left: 160px;
            } 
        </style>
        
        <div class="sidenav">
            <a href="#">About</a>
            <a href="index_gpt.html">Index</a>
        </div>
    <div class="header"><h3>ARISTOTLE</h3></div><p><span class="main">"Apixaban versus Warfarin in Patients with Atrial Fibrillation".The New England Journal of Medicine. 2011. 365:981-992. </span></p><p><span class="contents">
                                        Links to original sources:
                                        <a href=https://www.wikijournalclub.org//wiki/ARISTOTLE>Wiki Journal Post</a>
                                        <a href=http://www.nejm.org/doi/full/10.1056/NEJMoa1107039>Full Journal Article</a>
                                        </span></p><p><span class="main">1Clinical Question
2Bottom Line
3Major Points
4Guidelines
5Design
6Population
6.1Inclusion Criteria
6.2Exclusion Criteria
6.3Baseline Characteristics
7Interventions
8Outcomes
8.1Primary Outcome
8.2Secondary Outcomes
9Funding
10Further Reading
 </span></p><h2><span class="labels">Clinical Question</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">In patients with atrial fibrillation and at least one additional risk factor for stroke, is apixaban superior to warfarin in preventing stroke or systemic embolism?
 </span></p><h2><span class="labels">Bottom Line</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">In patients with atrial fibrillation, apixaban is superior to warfarin in preventing stroke or systemic embolism, causes less bleeding, and results in lower mortality.
 </span></p><h2><span class="labels">Major Points</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">Warfarin, effective in stroke prevention for patients with atrial fibrillation, is limited by its narrow therapeutic range, interactions, and bleeding risk. Apixaban, a factor Xa inhibitor, demonstrates superiority over warfarin in stroke prevention, fewer bleeding events, and reduced mortality.
 </span></p><h2><span class="labels">Guidelines</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">Current guidelines have not been explicitly adjusted to reflect the results of this trial.
 </span></p><h2><span class="labels">Design</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">Multicenter, double-blind, parallel-group, randomized, placebo-controlled trial
 </span></p><p><span class="main">N=18,201 patients with atrial fibrillation
Apixaban 5 mg PO BID (n=9120)
Warfarin to INR 2.0-3.0 (n=9081)
Setting: 1034 sites in 39 countries
Enrollment: 2006-2010
Median follow-up: 1.8 years
Analysis: Intention-to-treat
Primary Efficacy Outcome: Stroke or systemic embolism
Primary Safety Outcome: Major bleeding
 </span></p><h2><span class="labels">Population</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">Inclusion Criteria
Atrial fibrillation/flutter, at least one risk factor for stroke
 </span></p><p><span class="main">Exclusion Criteria
Reversible atrial fibrillation, moderate/severe mitral stenosis, conditions necessitating anticoagulation, recent stroke, aspirin >165 mg/day, severe renal impairment
 </span></p><p><span class="main">Baseline Characteristics
Median age: 70 years; 35.3% female; mean CHADS2 score: 2.1
 </span></p><h2><span class="labels">Interventions</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">Apixaban at a dose of 5 mg BID (2.5 mg BID in a subset)
Warfarin with INR target of 2.0-3.0
 </span></p><h2><span class="labels">Outcomes</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">Primary Outcome
Stroke or systemic embolism
Apixaban: 1.27% per year
Warfarin: 1.60% per year (HR 0.79; 95% CI, 0.66-0.95; P<0.001 for noninferiority; P=0.01 for superiority)
 </span></p><h2><span class="labels">Outcomes</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">Major bleeding
Apixaban: 2.13% per year
Warfarin: 3.09% per year (HR 0.69; 95% CI, 0.60-0.80; P<0.001)
Death from any cause
Apixaban: 3.52% per year
Warfarin: 3.94% per year (HR 0.89; 95% CI, 0.80-0.99; P=0.047)
 </span></p><h2><span class="labels">Funding</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">Bristol-Myers Squibb and Pfizer
 </span></p><h2><span class="labels">Further Reading</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">For more information, this study is registered on ClinicalTrials.gov, number NCT00412984. </span></p>    	
        <div class="footer">Footer</div>
        </body>
        </html>